Dr Meric-Bernstam on the Efficacy of T-DXd in HER2-Expressing Solid Tumors

Funda Meric-Bernstam, MD, discusses results from the phase 2 DESTINY-PanTumor02 trial of fam-trastuzumab deruxtecan-nxki in HER2-expressing solid tumors.

Related Keywords

Texas ,United States ,Nellieb Connally , ,Institute For Personalized Cancer Therapy ,University Of Texas Md Anderson Cancer Center ,Department Of Investigational Cancer Therapeutics ,Phasei Program ,Funda Meric Bernstam ,Investigational Cancer Therapeutics ,Personalized Cancer Therapy ,Breast Cancer ,Cancer Center ,The University Of Texas Md Anderson Cancer Center ,Onclive Tv ,Solid Tumors ,Ther2 ,Trastuzumab Deruxtecan ,The Phase 2 Destiny Pantumor02 Trial Nct04482309 ,